Cuprina (CUPR) forms wound care JV with Aiodine Laboratory

Cuprina Holdings (Cayman) Limited reported that it issued a press release on November 18, 2025 announcing the formation of a joint venture company with Aiodine Laboratory.

Rhea-AI Filing Summary

Cuprina Holdings (Cayman) Limited reported that it issued a press release on November 18, 2025 announcing the formation of a joint venture company with Aiodine Laboratory. The joint venture is intended to develop and market a novel iodine-based solution as a new wound care therapy. The press release describing this collaboration is included as Exhibit 99.1 to this Form 6-K.

Insights

Healthcare collaboration analyst

Cuprina discloses a new wound care joint venture via Form 6-K.

Cuprina Holdings (Cayman) Limited reports a press release about forming a joint venture company with Aiodine Laboratory. The stated goal is to develop and market a novel iodine-based solution as a new wound care therapy, indicating a focus on medical or healthcare applications.

The filing itself provides no financial terms, ownership structure, or timelines, so it mainly serves to formally notify markets of the collaboration. Any commercial impact will depend on how the joint venture advances product development and market adoption, details of which are not included in this excerpt.

Future company communications may expand on clinical development steps, regulatory pathways, or commercialization progress for the iodine-based wound care solution, which would help clarify how significant this joint venture could become for Cuprina's business.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cuprina Holdings (CUPR) announce in this Form 6-K?

Cuprina Holdings (Cayman) Limited announced that it issued a press release about forming a joint venture company with Aiodine Laboratory to develop and market a novel iodine-based solution as a new wound care therapy.

Who is Cuprina Holdings (CUPR) partnering with in the new joint venture?

Cuprina Holdings is partnering with Aiodine Laboratory in a joint venture company focused on developing and marketing a novel iodine-based wound care solution.

What is the focus of Cuprina Holdings' joint venture with Aiodine Laboratory?

The joint venture between Cuprina Holdings and Aiodine Laboratory aims to develop and market a novel iodine-based solution intended to be used as a new wound care therapy.

How is the joint venture announcement by Cuprina Holdings (CUPR) being communicated to investors?

The announcement is communicated through a Form 6-K, which states that a press release dated November 18, 2025 describing the joint venture is furnished as Exhibit 99.1.

Does this Cuprina Holdings Form 6-K include the full joint venture press release?

The Form 6-K states that the press release about the joint venture is furnished as Exhibit 99.1, indicating that the detailed announcement is attached as an exhibit rather than fully reproduced in the main body.

What type of SEC filing is used by Cuprina Holdings (CUPR) for this joint venture update?

Cuprina Holdings used a Form 6-K, which is a report of a foreign private issuer under the Securities Exchange Act, to furnish information about the joint venture press release.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/18/2025 - 08:30 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-42288

Cuprina Holdings (Cayman) Limited

(Registrant’s Name)

c/o Blk 1090 Lower Delta Road #06-08

Singapore 169201

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On November 18, 2025, Cuprina Holdings (Cayman) Limited (the “Company”) issued a press release announcing Cuprina forms Joint Venture Company with Aiodine Laboratory to Develop and Market Novel Iodine-based Solution as New Wound Care Therapy. This press release is furnished herewith as Exhibit 99.1.

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated November 18, 2025

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Cuprina Holdings (Cayman) Limited
	By:	/s/ David Quek Yong Qi
	Name:	David Quek Yong Qi
	Title:	Chief Executive Officer and Director

Date: November 18, 2025